Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation

Antiviral Therapy

Volumn 9, Issue 6, 2004, Pages 921-927

  Karasu, Zeki ^a   Ozacar, Tijen ^a   Akyildiz, Murat ^a   Demirbas, Tolga ^a   Arikan, Cigdem ^a   Kobat, Arzu ^a   Akarca, Ulus ^a   Ersoz, Galip ^a   Gunsar, Fulya ^a   Batur, Yucel ^a   Kilic, Murat ^a   Tokat, Yaman ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; VIRUS DNA;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DELTA AGENT HEPATITIS; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; VIRUS INFECTION; VIRUS REPLICATION;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 19944397810     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Demetris AJ, Todo S, Van Thiel DH, Fung JJ, Iwaki Y, Sysyn G, Ming W, Trager J & Starzl TE. Evolution of hepatitis B virus liver disease after hepatic replacement. American Journal of Pathology 1990; 137:667-676.
2. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ & Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13:619-626.
3. Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, Waters J, Kliem V, Muller R, Thomas HC & Manns MP. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24:489-493.
4. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM & Lok AS. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213-222.
5. Hunt CM, McGill JM, Allen ML & Condreay LD. Clinical relevance of hepatitis B virus mutations. Hepatology 2000; 31:1037-1044.
6. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL & Wright TL. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28:555-561.
7. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP & Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. New England Journal of Medicine 1993; 329:1842-1847.
8. Langrehr JM, Lemmens HP, Keck H, Lohmann R, Knoop M, Neumann U, Muller AR, Platz KP, Kling N & Hopf U. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis. Transplantation Proceedings 1995; 27:1215-1216.
9. Grazi GL, Mazziotti A, Sama C, Jovine E, Stefanini F, Paladini R, Rossi R & Cavallari A. Liver transplantation in HBsAg-positive HBV-DNA-negative cirrhotics: immunoprophylaxis and long-term outcome. Liver Transplantion & Surgery 1996; 2:418-425.
10. Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, Ryan TS, Kuhns M, McNamara A, Caldwell SH, Abdulkareem A & Pruett TL. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Annals of Surgery 1998; 227:841-850.
11. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL & Wright TL. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24:1327-1333.
12. Wiesner RH & Krom RAF. Liver transplantation for hepatitis B: the con aspect. Liver Transplantion & Surgery 1995; 1:265-270.
13. al-Hemsi B, McGory RW, Shepard B, Ishitani MB, Stevenson WC, McCullough C & Pruett TL. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clinical Transplantation 1996; 10:668-675.
14. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M & Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207-210.
15. Kitay-Cohen Y, Ben-Ari Z, Tur-Kaspa R, Fainguelernt H & Lishner M. Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis. Transplantation 2000; 69:2382-2383.
16. Bain VG, Kneteman NM, Ma MM, Gutfreund K, Shapiro JA, Fischer K, Tipples G, Lee H, Jewell LD & Tyrrell DL. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62:1456-1462.
17. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L & Brown N; Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424-432.
18. Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF, Fan ST & Wong J. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Annals of Surgery 2001; 233:276-281.
19. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E & Dusheiko G. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:1212-1215.
20. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, Bassendine M, O'Grady JG, Portmann BC, Anschuetz G, Barrett CA, Williams R & Atkins M. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Journal of Hepatology 2001; 34:888-894.
21. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, Shaw J, Burroughs N, Rand D, Cane P, Martin B, Buchan S, Boxall E, Barmat S, Gutekunst K, McMaster P & Elias E. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. Journal of Hepatology 1999; 30:715-721.
22. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP & Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-273.
23. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S & Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-180.
24. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ & Hoofnagle JH. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32:828-834.
25. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A & Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology 2000; 32:847-851.
26. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, Burroughs A, Hubscher S, Dhillon AP, Rolles K & Elias E. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70:809-815.
27. Fontana RJ, Keeffe EB, Han S, Wright T, Davis GL, Lilly L, Carey W, Fried M, Jensen D, Luketic V & Kowdley KV. Prevention of recurrent hepatitis B infection following liver transplantation: experience in 112 North American patients. Hepatology 1999; 30:301A.
28. Dienstag JL, Perrillo RP, Schiff ER, Bartholomey M, Vicary C & Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. New England Journal of Medicine 1995; 333:1657-1661.
29. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA & Thomas HC. Lamivudine therapy for chronic hepatitis B: a 6-month randomized dose-ranging study. Gastroenterology 1997; 113:1258-1263.
30. Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW & Schmidt JM. Dynamics of hepatitis B virus infection in vivo. Journal of Hepatology 1997; 27:431-436.
31. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N & Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:1670-1677.
32. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T & Opolon P. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Annals of Internal Medicine 1996; 125:705-712.
33. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, Dawson S, Goldstein L, Yersiz H, Farmer DG, Ghobrial RM, Busuttil RW & Martin P. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transplantation 2000; 6:741-748.
34. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R & Busuttil RW. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585-589.
35. Lee PH, Hu RH, Tsai MK, Ho MC, Lai HS, Lai MY & Yang PM. Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous anti-hepatitis B immunoglobulin and lamivudine. Transplantation Proceedings 2000; 32:2245-2247.
36. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, Kunder G, Chen PW, Farmer DG, Yersiz H, Baquerizo A, Geevarghese S, Han SH, Goldstein L, Holt CD, Gornbein JA & Busuttil RW. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Annals of Surgery 2002; 235:611-619.
37. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, Gentilcore E, Piantino P, Barbui AM, David E, Negro F & Rizzetto M. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. Journal of Hepatology 2001; 34:903-910.
38. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R & Gish RR. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transplantation & Surgery 1999; 5:491-496.
39. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, Eggen HJ & Steinbrecher UP. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transplantation & Surgery 1999; 5:520-525.
40. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP & Boker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. Journal of Hepatology 2001; 34:895-902.
41. McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, Verran D, Chui AK, Sheil AG, Jones RM, Locarnini SA & Angus PW. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose epatitis B immune globulin. Liver Transplantation & Surgery 1999; 5:512-519.
42. Angus PW, McCaughan GW, Gane EJ, Crawford DH & Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transplantation 2000; 6:429-433.
43. Lok ASF. Prevention of recurrent hepatitis B post-liver transplantation Liver Transplantation 2002; 8:S67-S73.
44. Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Riker-Hopkins M & Brown N; Lamivudine Compassionate Use Study Group. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transplantation 2001; 7:504-510.
45. Dienstag JL, Perrillo RP, Schiff ER, Bartholomey M, Vicary C & Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. New England Journal of Medicine 1995; 333:1657-1661.
46. Honkoop P, de Man RA, Niesters HG, Main J, Nevens F, Thomas HC, Fevery J, Tyrrell DL & Schalm SW. Quantitative hepatitis B virus DNA assessment by the limiting dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. Journal of Viral Hepatitis 1998; 5:307-312.
47. Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, DeVera A, Chen GT & Kellner A. Hepatitis B vaccine in medical staff of dialysis units. Efficacy and subtype cross-protection. New England Journal of Medicine 1982; 307:1481-1486.
48. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, Ostrow DG, O'Malley PM, Penley KA & Altman NL. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. New England Journal of Medicine 1986; 315:209-214.
49. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, Dussaix E, Guettier C, Bismuth H & Samuel D. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003; 38:86-95.